1-2 of 2
Nathalie Francillard
Close
Sort by
Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Jean-Jacques Kiladjian, MD PhD, Pierre Zachée, Masayuki Hino, MDPhD, Fabrizio Pane, Tamas Masszi, MD Prof., Claire N. Harrison, MD DM, FRCP, PRCPath, Ruben A. Mesa, MD, Carole B. Miller, MD, Francesco Passamonti, MD, Simon Durrant, FRCP,FRCPath,MBBS, Martin Griesshammer, MD PhD, Keita Kirito, MD, Carles Besses, MD PhD, Beatriz Moiraghi, Elisa Rumi, MD, Vittorio Rosti, MD, Igor W. Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1753.
https://doi.org/10.1182/blood-2018-99-115129
Published: 2018
Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Jean-Jacques Kiladjian, MD PhD, Srdan Verstovsek, MD PhD, Martin Griesshammer, Tamás Masszi, MD Prof., Simon Durrant, FRCP,FRCPath,MBBS, Francesco Passamonti, MD, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Keita Kirito, MD, Carlos Besses, MD PhD, Masayuki Hino, MDPhD, Ana Ines Varela, Carole B. Miller, MD, Elisa Rumi, MD, Vittorio Rosti, MD, Igor Wolfgang Blau, MD, Ruben A Mesa, MD, Tuochuan Dong, Nathalie Francillard, Mary Laughlin, Alessandro M. Vannucchi
Journal: Blood
Blood (2017) 130 (Supplement 1): 322.
https://doi.org/10.1182/blood.V130.Suppl_1.322.322
Published: 2017